STOCK TITAN
  1. Home
  2. Sec-filings
  3. WINT
  4. [8-K] Windtree Therapeutics, Inc. Reports Material Event

[8-K] Windtree Therapeutics, Inc. Reports Material Event

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Filing content is currently unavailable.

Source: View Original Filing on SEC EDGAR

Stock WINT logo
Windtree Therapeutics Inc

OTC:WINT

WINT Rankings

#6030 Ranked by Market Cap
N/A Ranked by Dividends

WINT Latest News

Sep 2, 2025
Windtree Therapeutics Stockholders Approve Key Proposals for Revenue and Profit Generation at the Special Stockholder Meeting
Aug 11, 2025
Windtree Announces Istaroxime has been Chosen for a Plenary Session Presentation at the Heart Failure Society of America 2025
Aug 5, 2025
Windtree Announces Istaroxime Phase 2 Interim Analysis in SCAI Stage C Cardiogenic Shock Patients
Jul 29, 2025
Windtree Therapeutics Announces Large Reduction of Preferred Series C and D Shares Outstanding by Conversion and Redemption
Jul 24, 2025
Windtree Therapeutics Announces Up To $520 Million in New Funding to Amplify BNB Cryptocurrency Treasury Strategy

WINT Latest SEC Filings

Aug 20, 2025
[8-K] Windtree Therapeutics, Inc. Reports Material Event
Aug 19, 2025
[10-Q] Windtree Therapeutics, Inc. Quarterly Earnings Report
Aug 14, 2025
[NT 10-Q] Windtree Therapeutics, Inc. SEC Filing
Aug 8, 2025
[DEF 14A] Windtree Therapeutics, Inc. Definitive Proxy Statement
Aug 8, 2025
[8-K] Windtree Therapeutics, Inc. Reports Material Event

WINT Stock Data

13.83M
29.33M
0%
0.08%
6.25%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
WARRINGTON